Parsabiv European Union - English - EMA (European Medicines Agency)

parsabiv

amgen europe b.v. - etelcalcetide hydrochloride - hyperparathyroidism, secondary - anti-parathyroid agents, calcium homeostasis - parsabiv is indicated for the treatment of secondary hyperparathyroidism (shpt) in adult patients with chronic kidney disease (ckd) on haemodialysis therapy.

PARSABIV Israel - English - Ministry of Health

parsabiv

amgen europe b.v. - etelcalcetide as hydrochloride - solution for injection - etelcalcetide as hydrochloride 5 mg / 1 ml - etelcalcetide - parsabiv is indicated for the treatment of secondary hyperparathyroidism (shpt) in adult patients with chronic kidney disease (ckd) on hemodialysis therapy.

PARSABIV SOLUTION FOR INJECTION 10 mg2 mL Singapore - English - HSA (Health Sciences Authority)

parsabiv solution for injection 10 mg2 ml

amgen biotechnology singapore pte ltd - etelcalcetide hydrochloride 11.54 mg eqv etelcalcetide - injection, solution - etelcalcetide hydrochloride 11.54 mg eqv etelcalcetide 10 mg/2 ml

PARSABIV SOLUTION FOR INJECTION 2.5 mg0.5 mL Singapore - English - HSA (Health Sciences Authority)

parsabiv solution for injection 2.5 mg0.5 ml

amgen biotechnology singapore pte ltd - etelcalcetide hydrochloride 2.88 mg eqv etelcalcetide - injection, solution - etelcalcetide hydrochloride 2.88 mg eqv etelcalcetide 2.5 mg/0.5 ml

PARSABIV SOLUTION FOR INJECTION 5 mgmL Singapore - English - HSA (Health Sciences Authority)

parsabiv solution for injection 5 mgml

amgen biotechnology singapore pte ltd - etelcalcetide hydrochloride 5.77 mg eqv etelcalcetide - injection, solution - etelcalcetide hydrochloride 5.77 mg eqv etelcalcetide 5 mg/ml